[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200500881A1 - N-арилсульфонил-3-замещенные индолы, обладающие афинностью к серотониновому рецептору, способ их получения и содержащая их фармацевтическая композиция - Google Patents

N-арилсульфонил-3-замещенные индолы, обладающие афинностью к серотониновому рецептору, способ их получения и содержащая их фармацевтическая композиция

Info

Publication number
EA200500881A1
EA200500881A1 EA200500881A EA200500881A EA200500881A1 EA 200500881 A1 EA200500881 A1 EA 200500881A1 EA 200500881 A EA200500881 A EA 200500881A EA 200500881 A EA200500881 A EA 200500881A EA 200500881 A1 EA200500881 A1 EA 200500881A1
Authority
EA
Eurasian Patent Office
Prior art keywords
arylsulphone
affinity
receiving
pharmaceutical composition
serotonin receptor
Prior art date
Application number
EA200500881A
Other languages
English (en)
Other versions
EA011320B1 (ru
Inventor
Венката Сатья Нироги Рамакришна
Викас Шрикришна Ширсатх
Рама Састри Камбхампати
Венката Сатья Веерабхадра Вадламуди Рао
Венкатесварлу Джасти
Original Assignee
Сувен Лайф Сайенсиз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сувен Лайф Сайенсиз Лимитед filed Critical Сувен Лайф Сайенсиз Лимитед
Publication of EA200500881A1 publication Critical patent/EA200500881A1/ru
Publication of EA011320B1 publication Critical patent/EA011320B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)

Abstract

Настоящее изобретение относится к новым N-арилсульфонил-3-замещенным индольным соединениям, их производным, их аналогам, их таутомерным формам, их стереоизомерам, их геометрическим формам, их N-оксидам, их полиморфам, их фармацевтически приемлемым солям, их фармацевтически приемлемым сольватам и содержащим их фармацевтически приемлемым композициям. Настоящее изобретение, в частности, относится к новым N-арилсульфонил-3-замещенным индолам общей формулы (I), их производным, их аналогам, их таутомерным формам, их стереоизомерам, их геометрическим формам, их полиморфам, их фармацевтически приемлемым солям, их фармацевтически приемлемым сольватам и содержащим их фармацевтически приемлемым композициям. Настоящее изобретение также относится к способу получения соединений общей формулы (I), фармацевтических композиций, содержащих такие соединения, и к применению таких соединений и композиций в медицине. Настоящее изобретение также относится к новым используемым промежуточным соединениям и к способу их получения.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200500881A 2002-11-28 2003-06-05 N-арилсульфонил-3-замещенные индолы, обладающие афинностью к серотониновому рецептору, способ их получения и содержащая их фармацевтическая композиция EA011320B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN884MA2002 2002-11-28
PCT/IN2003/000209 WO2004048330A1 (en) 2002-11-28 2003-06-05 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them

Publications (2)

Publication Number Publication Date
EA200500881A1 true EA200500881A1 (ru) 2005-12-29
EA011320B1 EA011320B1 (ru) 2009-02-27

Family

ID=40184827

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500881A EA011320B1 (ru) 2002-11-28 2003-06-05 N-арилсульфонил-3-замещенные индолы, обладающие афинностью к серотониновому рецептору, способ их получения и содержащая их фармацевтическая композиция

Country Status (22)

Country Link
US (1) US7875605B2 (ru)
EP (1) EP1581492B1 (ru)
JP (1) JP4559230B2 (ru)
KR (1) KR100818508B1 (ru)
CN (2) CN101544592B (ru)
AT (1) ATE401307T1 (ru)
AU (1) AU2003237599B2 (ru)
BR (2) BRPI0315959C1 (ru)
CA (1) CA2509982C (ru)
CY (1) CY1108786T1 (ru)
DE (1) DE60322266D1 (ru)
DK (1) DK1581492T3 (ru)
EA (1) EA011320B1 (ru)
ES (1) ES2310243T3 (ru)
HK (2) HK1083217A1 (ru)
MX (1) MXPA05005701A (ru)
NO (2) NO330341B1 (ru)
NZ (2) NZ572186A (ru)
PT (1) PT1581492E (ru)
SI (1) SI1581492T1 (ru)
WO (1) WO2004048330A1 (ru)
ZA (1) ZA200504043B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE401072T1 (de) * 2002-02-12 2008-08-15 Organon Nv 1-arylsulfonyl-3-substituierte indol und indolinederivate verwendbar zur behandlung von erkrankungen des zentralnervensystem
WO2005005439A1 (en) * 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
WO2005066184A1 (en) 2004-01-02 2005-07-21 Suven Life Sciences Limited Novel indeno[2,1a]indenes and isoindol[2,1-a]indoles
CA2616937A1 (en) 2005-07-29 2007-02-08 F. Hoffman-La Roche Ag Indol-3-yl-carbonyl-piperidin and piperazin derivatives
PL1919896T3 (pl) 2005-08-12 2010-05-31 Suven Life Sciences Ltd Pochodne aminoarylosulfonamidu jako funkcjonalne ligandy 5-HT6
WO2007020653A1 (en) * 2005-08-12 2007-02-22 Suven Life Sciences Limited Thioether derivatives as functional 5-ht6 ligands
US7923566B2 (en) 2005-08-16 2011-04-12 Suven Life Sciences Limited Alternative process for the preparation of losartan
PL2114878T3 (pl) * 2007-01-08 2011-05-31 Suven Life Sciences Ltd Związki 5-(heterocyklilo)alkilo-N-(arylosulfonylo)indolowe i ich zastosowanie jako ligandy 5-HT6
CA2672190C (en) * 2007-01-08 2013-02-05 Suven Life Sciences Limited 4-(heterocyclyl)alkyl-n-(arylsulfonyl) indole compounds and their use as 5-ht6 ligands
DK2155674T3 (da) 2007-05-03 2011-09-26 Suven Life Sciences Ltd Aminoalkoxy-aryl-sulfonamidforbindelser og anvendelse heraf som 5-HT6-ligander
US7807705B2 (en) * 2007-05-18 2010-10-05 The Ohio State University Research Foundation Potent indole-3-carbinol-derived antitumor agents
WO2009053997A1 (en) 2007-10-26 2009-04-30 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-ht6 ligands
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
CN102159564B (zh) 2008-09-17 2014-06-18 苏文生命科学有限公司 芳基磺酰胺胺化合物及它们作为5-ht6配体的用途
WO2011019738A1 (en) * 2009-08-10 2011-02-17 Galenea Corporation Compounds and methods of use thereof
US8153680B2 (en) * 2009-08-25 2012-04-10 The Ohio State University Research Foundation Alkyl indole-3-carbinol-derived antitumor agents
DK2521714T3 (en) 2010-01-05 2015-10-19 Suven Life Sciences Ltd Aromatic sulfone compositions useful in the treatment of central nervous disorders
CN102093149A (zh) * 2010-12-08 2011-06-15 天津理工大学 一种促进氰基快速水解制备羧酸类化合物的方法
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
KR101534136B1 (ko) * 2013-06-11 2015-07-07 이화여자대학교 산학협력단 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 5-ht6 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
WO2015083179A1 (en) 2013-12-02 2015-06-11 Suven Life Sciences Limited Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
WO2015090233A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
WO2016004882A1 (en) 2014-07-08 2016-01-14 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
NZ728907A (en) * 2014-08-16 2017-12-22 Suven Life Sciences Ltd Active metabolite of 1-[(2-bromophenyl) sulfonyl]-5-methoxy-3- [(4-methyl-1-piperazinyl) methyl]-1h-indole dimesylate monohydrate and dimesylate dihydrate salt of active metabolite
NZ747797A (en) * 2016-05-18 2020-07-31 Suven Life Sciences Ltd Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist
NZ747778A (en) * 2016-05-18 2020-03-27 Suven Life Sciences Ltd Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist
MD3484467T2 (ro) 2016-05-18 2020-06-30 Suven Life Sciences Ltd Combinație de antagoniști ai receptorilor 5-HT6 puri cu inhibitori ai acetilcolinesterazei
HUE055452T2 (hu) 2016-10-03 2021-11-29 Suven Life Sciences Ltd 5-HT6 antagonista gyógyszerkészítmények
CN107174586B (zh) * 2017-02-21 2020-08-11 中国科学院昆明植物研究所 以芦竹碱衍生物为活性成分的药物组合物及其应用
US20210338661A1 (en) * 2017-07-03 2021-11-04 Suven Life Sciences Limited New uses of a pure 5-ht 6 receptor antagonist
MX2022006537A (es) 2019-12-02 2022-12-13 Suven Life Sciences Ltd Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia.
AU2020398082A1 (en) 2019-12-02 2022-06-16 Suven Life Sciences Limited Treating behavioral and psychological symptoms in dementia patients
CN111233737B (zh) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途
CN111362858B (zh) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途
KR102347372B1 (ko) 2020-12-14 2022-01-07 (주)케이메디켐 신규한 인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물
CN115504925B (zh) * 2021-06-22 2024-03-12 广东药科大学 一类ppar激动剂、其制备方法及其作为药物的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1305458A (ru) * 1969-02-26 1973-01-31
ZA795239B (en) 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
JPH04208263A (ja) * 1990-01-02 1992-07-29 Fujisawa Pharmaceut Co Ltd インドール誘導体およびそれらの製造法
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
CA2042295A1 (fr) 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
PT97888B (pt) 1990-06-07 1998-12-31 Zeneca Ltd Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
SK278998B6 (sk) 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
TW263508B (ru) 1991-02-12 1995-11-21 Pfizer
GB9113802D0 (en) 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
JP3223193B2 (ja) * 1991-08-09 2001-10-29 株式会社日清製粉グループ本社 インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質
GB9210400D0 (en) 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
KR940007001A (ko) 1992-09-16 1994-04-26 최승주 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제
JP3155008B2 (ja) * 1994-07-26 2001-04-09 ファイザー・インコーポレーテッド セロトニンアゴニストおよびアンタゴニストとしての４−インドール誘導体
AU778682B2 (en) * 1999-04-21 2004-12-16 Nps Pharmaceuticals, Inc. Piperidine-indole compounds having 5-HT6 affinity
JP2000344744A (ja) 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
PE20020276A1 (es) * 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
CN1317276C (zh) * 2000-09-29 2007-05-23 中国科学院上海药物研究所 一类吲哚基哌啶类化合物及其制备方法和用途
MXPA03003397A (es) * 2000-10-20 2004-06-30 Biovitrum Ab N1-(bencensulfonil)indoles sustituidos en las posiciones 2-, 3-, 4-, o 5 y su uso en terapia.
EP1335722B1 (en) * 2000-11-24 2006-08-30 Smithkline Beecham Plc Indolyl-sulfonyl- compounds useful in the treatment of cns disorders
US20040039017A1 (en) * 2000-12-11 2004-02-26 Dashyant Dhanak Urotensin-II receptor antagonists
DK1355900T3 (da) * 2000-12-22 2006-09-11 Wyeth Corp Heterocyclylalkylindol- eller -azaindolforbindelser som 5-hydroxytryptamin-6-ligander
WO2002058702A1 (en) * 2001-01-26 2002-08-01 Smithkline Beecham Corporation Urotensin-ii receptor antagonists
ATE401072T1 (de) * 2002-02-12 2008-08-15 Organon Nv 1-arylsulfonyl-3-substituierte indol und indolinederivate verwendbar zur behandlung von erkrankungen des zentralnervensystem

Also Published As

Publication number Publication date
PT1581492E (pt) 2008-09-19
EA011320B1 (ru) 2009-02-27
EP1581492B1 (en) 2008-07-16
KR100818508B1 (ko) 2008-03-31
JP2006514011A (ja) 2006-04-27
CN101544592B (zh) 2013-08-21
NO20052737D0 (no) 2005-06-08
JP4559230B2 (ja) 2010-10-06
CY1108786T1 (el) 2014-04-09
CN1720225A (zh) 2006-01-11
ES2310243T3 (es) 2009-01-01
BR0315959A (pt) 2005-09-13
NZ572186A (en) 2010-02-26
EP1581492A1 (en) 2005-10-05
BRPI0315959B8 (pt) 2018-01-16
CA2509982C (en) 2011-11-08
US20060223890A1 (en) 2006-10-05
SI1581492T1 (sl) 2008-12-31
CN1720225B (zh) 2011-05-18
AU2003237599A1 (en) 2004-06-18
BRPI0318799B1 (pt) 2019-06-25
NO20085054L (no) 2005-08-25
BRPI0318799B8 (pt) 2021-05-25
MXPA05005701A (es) 2005-08-16
CA2509982A1 (en) 2004-06-10
CN101544592A (zh) 2009-09-30
US7875605B2 (en) 2011-01-25
KR20050086868A (ko) 2005-08-30
BRPI0315959B1 (pt) 2017-12-19
WO2004048330A8 (en) 2005-10-27
DE60322266D1 (de) 2008-08-28
NO20052737L (no) 2005-08-25
NZ540840A (en) 2008-12-24
WO2004048330A1 (en) 2004-06-10
HK1083217A1 (en) 2006-06-30
DK1581492T3 (da) 2008-11-10
NO335015B1 (no) 2014-08-25
ATE401307T1 (de) 2008-08-15
BRPI0315959C1 (pt) 2021-05-25
NO330341B1 (no) 2011-03-28
HK1133002A1 (ru) 2010-03-12
AU2003237599B2 (en) 2009-06-18
ZA200504043B (en) 2006-07-26

Similar Documents

Publication Publication Date Title
EA200500881A1 (ru) N-арилсульфонил-3-замещенные индолы, обладающие афинностью к серотониновому рецептору, способ их получения и содержащая их фармацевтическая композиция
PE20050419A1 (es) Compuestos de pirazol e imidazol biciclicos como ligandos de receptores cannabinoides
EA200600925A1 (ru) Производные триазола в качестве антагонистов вазопрессина
EA199700156A1 (ru) Производные индола как антагонисты рецептора 5-нт
EA200600348A1 (ru) Новые соединения
NO20062139L (no) Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister
EA200901253A1 (ru) ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
MXPA03000161A (es) Compuestos novedosos los cuales tienen actividad antiinflamatoria, proceso para su preparacion y composiciones farmaceuticas que las contienen.
ATE359782T1 (de) Heteroaryl-substituierte pyrrol(2, 3- b)pyridin- derivate als crf-rezeptor-antagonisten
WO2004055026A8 (en) Tetracyclic 3-substituted indoles having serotonin receptor affinity
ATE505462T1 (de) Neue biologischaktive molekü le
DK1523486T3 (da) Tetracykliske arylsulfonylindoler med serotoninreceptor-affinitet
DK1537113T3 (da) Arylalkylindoler med serotoninreceptoraffinitet anvendelige som terapeutiske midler, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
EA201001459A1 (ru) 2-амино-3-сульфонил-тетрагидропиразоло[1,5-а]пиридопиримидины - антагонисты серотониновых 5-нтрецепторов, способы их получения и применения
DK1517909T3 (da) Tetracykliske arylcarbonylindoler med serotoninreceptor-affinitet til anvendelse som terpaeutiske midler, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger indeholdende dem
AR052332A1 (es) Derivados de benzdioxanpiperazina con una afinidad combinada para receptores de dopamina-d2 y sitios de reabsorcion de serotonina, composiciones farmaceuticas que los contienen y su empleo como medicamentos para el tratamiento de enfermedades del snc
EA200300238A1 (ru) Триазольные производные и фармацевтические композиции, содержащие их
AR014354A1 (es) Derivados de 3,4,5,6,7,8-hexahidro-pirido (3',4':4,5) tieno[2,3-d]pirimidina 3-sustituidos y su uso para la preparacion de composiciones farmaceuticas.